2025-10-05 - Analysis Report
Okay, here's an analysis of TG Therapeutics (TGTX) based on the data provided, presented in English with key numbers and analysis:

## TGTX Analysis

**Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

### 1. Performance vs. S&P 500 (VOO)

*   **TGTX Cumulative Return:** 93.65%
*   **VOO Cumulative Return:** 98.51%
*   **Absolute Deviation:** -5.1% (TGTX is underperforming VOO by 5.1%)
*   **Relative Deviation:** 23.6 (TGTX's current deviation is at the 23.6th percentile of its historical deviation range compared to VOO.)

**Analysis:** TGTX has underperformed the S&P 500 recently, and its relative deviation is at the lower end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha    | Beta  | Cap(B) |
|------------|---------|-------|----------|-------|--------|
| 2015-2017  | -5.0%   | 73.5% | -33.0%   | -0.0  | 1.3    |
| 2016-2018  | -12.0%  | 73.5% | -27.0%   | -0.0  | 0.7    |
| 2017-2019  | 74.0%   | 74.1% | 52.0%    | 0.0   | 1.8    |
| 2018-2020  | 316.0%  | 74.1% | 293.0%   | 0.1   | 8.2    |
| 2019-2021  | 124.0%  | 74.1% | 78.0%    | 0.3   | 3.0    |
| 2020-2022  | -71.0%  | 77.8% | -71.0%   | -0.0  | 1.9    |
| 2021-2023  | -284.0% | 77.8% | -285.0%  | -1.1  | 2.7    |
| 2022-2024  | 56.0%   | 77.8% | 36.0%    | -1.0  | 4.8    |
| 2023-2025  | 94.0%   | 74.8% | 31.0%    | -0.1  | 5.8    |

**Analysis:**

*   **CAGR:** Highly variable, with periods of significant growth (e.g., 2018-2020) and sharp declines (e.g., 2021-2023).
*   **MDD:** Consistently high, indicating substantial risk and volatility.
*   **Alpha:** Fluctuates significantly.  Periods with positive Alpha (outperformance relative to the market) are interspersed with periods of substantial negative Alpha.
*   **Beta:** Generally low (close to 0), indicating TGTX's price is relatively insensitive to market movements. However, the beta has been showing a decreasing trend in recent years.

### 2. Recent Price Action

*   **Current Price:** $36.705
*   **Last Market Change:** Price: 36.705, Previous Close: 36.66, Change: 0.12
*   **5-day Moving Average:** 36.492
*   **20-day Moving Average:** 34.01
*   **60-day Moving Average:** 32.7287

**Analysis:**

*   The price is currently above all three moving averages (5, 20, and 60 days), suggesting an upward trend.
*   The 5-day moving average is above the 20-day moving average, which is above the 60-day moving average, further supporting a short-term bullish trend.
*   The small change from the previous close doesn't indicate a major volatility event.

### 3. Technical Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 80.99 (Overbought)
*   **PPO:** 0.7879
*   **Hybrid Signal:** Buy 100% of cash (27 shares - Very Safe - MRI:0.90). Monthly invest 0.8% of total investment ($1,000.00).
*   **Delta_Previous_Relative_Divergence:** 1.8 (+, Short-term increase)
*   **Expected Return:** -93.4% (Long-term underperformance vs. S&P 500 if investing at this point.)

**Analysis:**

*   **MRI:** Suggests the market conditions are favorable for investment.
*   **RSI:** The high RSI indicates that the stock may be overbought and a correction is possible.
*   **PPO:** Indicates the direction of a trend, can be used to detect overbought and oversold conditions.
*   **Delta:** Suggests a recent increase in relative outperformance.
*   **Expected Return:**  The significantly negative expected return indicates a high degree of caution is warranted despite the recent positive price action and MRI.

### 4. Recent News & Significant Events

*   **Institutional Investment:** Institutional investors have been rewarded for their investment in TGTX.
*   **BRIUMVI Safety Data:** Six-year safety data for BRIUMVI is positive for shareholders.
*   **BRIUMVI Data on Multiple Sclerosis:**  Data shows a high percentage of MS patients are free from progression after 6 years of BRIUMVI treatment.
*   **Neuraxpharm Participation:** Neuraxpharm's involvement in ECTRIMS reinforces its commitment to multiple sclerosis.

**Analysis:** The recent news is overwhelmingly positive, focusing on institutional investment gains and strong clinical data for BRIUMVI in treating multiple sclerosis. This positive news likely contributes to the recent upward price momentum.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean rating: 1.75)
*   **Target Price:** Average $40.83, High $55.00, Low $11.00
*   **Recent Rating Changes:**  No changes indicated.

**Analysis:** Analyst consensus is strongly positive, with a "Buy" rating and an average target price above the current price. However, the wide range in target prices suggests uncertainty.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출    |
|------------|------|---------|
| 2025-08-08 | 0.19 | 0.14 B$ |
| 2025-05-09 | 0.03 | 0.12 B$ |
| 2024-11-07 | 0.03 | 0.08 B$ |
| 2024-08-09 | 0.05 | 0.07 B$ |
| 2025-08-08 | 0.05 | 0.07 B$ |

**Analysis:**

*   EPS (Earnings Per Share) has been fluctuating, with a recent spike in 2025-08-08.
*   Revenue shows a general upward trend over the reported quarters.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-06-30   | $0.14B   | 86.58%       |
| 2025-03-31   | $0.12B   | 87.14%       |
| 2024-12-31   | $0.11B   | 85.77%       |
| 2024-09-30   | $0.08B   | 88.86%       |
| 2024-06-30   | $0.07B   | 88.70%       |

**Capital and Profitability:**

| Quarter      | Equity   | ROE      |
|--------------|----------|----------|
| 2025-06-30   | $0.28B   | 10.20%   |
| 2025-03-31   | $0.24B   | 2.13%    |
| 2024-12-31   | $0.22B   | 10.49%   |
| 2024-09-30   | $0.19B   | 2.02%    |
| 2024-06-30   | $0.18B   | 3.87%    |

**Analysis:**

*   **Revenue:** Increasing trend, suggesting business growth.
*   **Profit Margin:** Consistently high, indicating efficient operations.
*   **Equity:** Increasing trend, reflecting the growth in the company's net assets.
*   **ROE (Return on Equity):** Fluctuates, but generally shows periods of strong profitability relative to equity.

### 7. 종합 분석 (Overall Assessment)

TGTX presents a mixed picture.

*   **Positives:**
    *   Recent positive news related to BRIUMVI clinical data and institutional investment.
    *   Strong analyst consensus (Buy rating).
    *   Increasing revenue and high profit margins.
    *   High Market Risk Indicator.
    *   The short-term trend is positive, with the price above its moving averages.
    *   Buy Signal.
*   **Negatives:**
    *   Underperformance compared to the S&P 500 (VOO).
    *   Extremely high RSI, indicating it is potentially overbought.
    *   Historical volatility and significant drawdowns.
    *   Significantly negative expected return, indicating substantial long-term risk.
    *   Beta is showing a decreasing trend in recent years.

**Conclusion:**

TGTX appears to be experiencing a period of positive momentum driven by promising clinical data and analyst sentiment. The strong revenue growth and high profit margins are also encouraging. However, the stock remains risky due to its historical volatility, underperformance relative to the S&P 500, and negative expected return. Investors should exercise caution and carefully consider their risk tolerance before investing in TGTX. The overbought RSI suggests a potential pullback is possible.
